Yuan Lei

Hebei University

SCHOLARLY PAPERS

1

DOWNLOADS

48

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

ARX788 Versus Lapatinib Plus Capecitabine in the Second-Line Treatment of HER2-Positive Advanced Breast Cancer (ACE-Breast-02): A Multicentre, Open-Label, Phase III, Randomised Controlled Trial

Number of pages: 26 Posted: 10 Jul 2024
Fudan University - Department of Medical Oncology, Harbin Medical University - Cancer Hospital, Fudan University - Department of Oncology, Fudan University - Department of Medical Oncology, Central South University - Hunan Cancer Hospital, Chinese Academy of Sciences (CAS) - Cancer Hospital, Jilin Central Hospital, Guangxi Medical University, Tianjin Medical University - Tianjin Cancer Institute, Sun Yat-sen University (SYSU) - Sun Yat-Sen University Cancer Center, Chongqing University Cancer Hospital, Dalian University of Technology - Liaoning Cancer Institute and Hospital, Xinjiang Medical University, Anhui Medical University - Second Affiliated Hospital, Hainan Medical University - First Affiliated Hospital, Sun Yat-sen University, Hainan Medical University - Hainan General Hospital, Zhengzhou University, Henan University of Science and Technology - Department of Medical Oncology, Linyi Cancer Hospital - Department of Breast Surgery, Wenzhou Medical University, Anhui Medical University - Department of Oncology, Government of the People's Republic of China - Beijing Hospital, Xiamen University - First Affiliated Hospital, Xinxiang Medical University - First Affiliated Hospital, Xuzhou Central Hospital, Sanmenxia Central Hospital, Hebei University - Department of Medical Oncology, Hebei University and Hebei University
Downloads 48 (868,838)

Abstract:

Loading...

HER2-positive, antibody-drug conjugates, advanced breast cancer.